Clinical-stage biotechnology company developing the Bisphosphocin class of fast-acting, broad-spectrum antimicrobials to treat infectious diseases and counter antibiotic-resistant bacterial strains including MRSA and VRE.
Phase 2a readout timing for NU-3 in infected diabetic foot ulcers
Lakewood-Amedex Biotherapeutics said the first patient has been dosed in a Phase 2a trial of NU-3 for infected diabetic foot ulcers.
Chief Executive Officer and SVP Research & Development
Chief Medical Officer and SVP Clinical Development
Chief Financial Officer and VP Administration